Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

Faries, Douglas; Ascher-Svanum, Haya; Baojin Zhu; Correll, Christoph; Kane, John
January 2005
BMC Psychiatry;2005, Vol. 5, p26
Academic Journal
Background: Antipsychotic monotherapy is recognized as the treatment of choice for patients with schizophrenia. Simultaneous treatment with multiple antipsychotics (polypharmacy) is suggested by some expert consensus guidelines as the last resort after exhausting monotherapy alternatives. This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications. Methods: Data were drawn from a large prospective naturalistic study of patients treated for schizophrenia-spectrum disorders, conducted 7/1997-9/2003. Analyses focused on patients (N = 796) who were initiated during the study on olanzapine (N = 405), quetiapine (N = 115), or risperidone (N = 276). The percentage of patients with monotherapy on the index antipsychotic over the 1-year post initiation, and the cumulative number of days on monotherapy were calculated for all patients and for each of the 3 atypical antipsychotic treatment groups. Analyses employed repeated measures generalized linear models and non-parametric bootstrap re-sampling, controlling for patient characteristics. Results: During the 1-year period, only a third (35.7%) of the patients were treated predominately with monotherapy (>300 days). Most patients (57.7%) had at least one prolonged period of antipsychotic polypharmacy (>60 consecutive days). Patients averaged 195.5 days on monotherapy, 155.7 days on polypharmacy, and 13.9 days without antipsychotic therapy. Olanzapine-initiated patients were significantly more likely to be on monotherapy with the initiating antipsychotic during the 1-year post initiation compared to risperidone (p = .043) or quetiapine (p = .002). The number of monotherapy days was significantly greater for olanzapine than quetiapine (p < .001), but not for olanzapine versus risperidone, or for risperidone versus quetiapine-initiated patients. Conclusion: Despite guidelines recommending the use of polypharmacy only as a last resort, the use of antipsychotic polypharmacy for prolonged periods is very common during the treatment of schizophrenia patients in usual care settings. In addition, in this non-randomized naturalistic observational study, the most commonly used atypical antipsychotics significantly differed on the rate and duration of antipsychotic monotherapy. Reasons for and the impact of the predominant use of polypharmacy will require further study.


Related Articles

  • Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications. Karthik, M. S.; Warikoo, Nisha; Chakrabarti, Subho; Grover, Sandeep; Kulhara, Parmanand // Indian Journal of Psychological Medicine;Jul-Sep2014, Vol. 36 Issue 3, p288 

    Background: Given the paucity of research in this area, this study attempted to assess attitudes toward antipsychotic medications and its correlates among patients with schizophrenia, either on first-generation antipsychotics (FGAs) or second-generation antipsychotics (SGAs) medications....

  • The Lifetime Outcome and Involuntary Movements of Schizophrenia Never Treated with Neuroleptic Drugs: Four Rare Cases in Ireland. Waddington, John L.; Youssef, Hanafy A. // British Journal of Psychiatry;Jan90, Vol. 156, p106 

    Four elderly schizophrenic patients who had never been treated with neuroleptics, and a fifth patient who had received only the briefest exposure to such drugs, had retained their distinct clinical characteristics. Involuntary orofacial movements and cognitive dysfunction were found more...

  • Pervasive Developmental Disorders and Psychoses in Adult Life. Clarke, David J.; Littlejohns, Carl S.; Corbett, John A.; Joseph, Susan // British Journal of Psychiatry;Nov89, Vol. 155, p692 

    Of five patients with pervasive developmental disorders (PDDs), four developed psychotic illnesses in adult life. The other was treated with antipsychotic medication for many years following a mistaken diagnosis of schizophrenia.

  • The Clinical Correlates of Neurological Soft Signs in Chronic Schizophrenia. King, D. J.; Wilson, A.; Cooper, S. J.; Waddington, J. L. // British Journal of Psychiatry;Jun91, Vol. 158, p770 

    Among 16 chronic schizophrenic in-patients, all had at least one neurological soft sign (NSS), and 6 (40%) had definite neurodysfunction. NSS and TD scores were highly intercorrelated, and NSS were significantly correlated with neuroleptic drug exposure. NSS correlated positively with both...

  • Behavioural Vigilance in Schizophrenia: Evidence for Hyperattentional Processing. Mar, Corinne M.; Smith, David A.; Sarter, Martin // British Journal of Psychiatry;Dec96, Vol. 169, p781 

    Background. Despite 30 years of research, some surprisingly fundamental gaps remain in our understanding of schizophrenic input dysfunctions. Method. In a provisional test of a `hyperattention' hypothesis, schizophrenic patients and control subjects performed a behavioural test that was adapted...

  • A Comparison of Academic and Lay Theories of Schizophrenia. Furnham, A.; Bower, P. // British Journal of Psychiatry;Aug92, Vol. 161, p201 

    This study investigated lay subjects' theories of schizophrenia. A questionnaire examining the five identified main academic theories of schizophrenia (medical, moral-behavioural, social, psychoanalytic, and conspiratorial) along various dimensions (aetiology, behaviour, treatment, function of...

  • Lack of Insight in Schizophrenia: Impact on Treatment Adherence. Buckley, Peter F.; Wirshing, Donna A.; Bhushan, Prameet; Pierre, Joseph M.; Resnick, Seth A.; Wirshing, William C. // CNS Drugs;2007, Vol. 21 Issue 2, p129 

    People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now...

  • A study of cranial computertomograms in very early and early onset schizophrenia. Badura, F.; Trott, G.-E.; Mehler-Wex, C.; Scheuerpflug, P.; Hofmann, E.; Warmuth-Metz, M.; Nadjmi, M.; Solymosi, L.; Warnke, A. // Journal of Neural Transmission;Nov2001, Vol. 108 Issue 11, p1335 

    Summary. The cranial computer-assisted tomograms of 19 patients suffering from schizophrenic psychoses with onset by age of 14 were examined. The emphasis was on the extent of the inner liquor spaces. Compared to healthy controls, at the beginning of illness a significant enlargement was...

  • Labeling-stereotype-discrimination. Angermeyer, Matthias; Matschinger, Herbert // Social Psychiatry & Psychiatric Epidemiology;May2005, Vol. 40 Issue 5, p391 

    Aim Using Link and Phelan's concept of the stigma process, public attitudes towards people with schizophrenia are examined. Method In the spring of 2001, a representative population survey was conducted in Germany (n = 5025). A fully structured personal interview was carried out, beginning with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics